Cancers, Vol. 13, Pages 1922: Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma
Cancers, Vol. 13, Pages 1922: Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma
Cancers doi: 10.3390/cancers13081922
Authors:
Julia Peña-Asensio
Henar Calvo
Miguel Torralba
Joaquín Miquel
Eduardo Sanz-de-Villalobos
Juan-Ramón Larrubia
Thirty to fifty percent of hepatocellular carcinomas (HCC) display an immune class genetic signature. In this type of tumor, HCC-specific CD8 T cells carry out a key role in HCC control. Those potential reactive HCC-specific CD8 T cells recognize either HCC immunogenic neoantigens or aberrantly expressed host’s antigens, but they become progressively exhausted or deleted. These cells express the negative immunoregulatory checkpoint programmed cell death protein 1 (PD-1) which impairs T cell receptor signaling by blocking the CD28 positive co-stimulatory signal. The pool of CD8 cells sensitive to anti-PD-1/PD-L1 treatment is the PD-1dim memory-like precursor pool that gives rise to the effector subset involved in HCC control. Due to the epigenetic imprints that are transmitted to the next generation, the effect of PD-1 blockade is transient, and repeated treatments lead to tumor resistance. During long-lasting disease, besides the TCR signaling impairment, T cells develop other failures that should be also set-up to increase T cell reactivity. Therefore, several PD-1 blockade-based combinatory therapies are currently under investigation such as adding ...
Source: Cancers - Category: Cancer & Oncology Authors: Julia Pe ña-Asensio Henar Calvo Miguel Torralba Joaqu ín Miquel Eduardo Sanz-de-Villalobos Juan-Ram ón Larrubia Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Hepatocellular Carcinoma | Immunotherapy | Liver Cancer